Cytarabine

Essential medicine status

General description

Cytarabine is a pyrimidine nucleoside analogue antineoplastic agent used in the treatment of leukaemias and lymphomas.

INN	Cytarabine
ATC codes	L01BC01
Medicine type	Chemical agent
EML status history	First added in 1979 (TRS 641) for Lymphoid leukaemia, not elsewhere classified Added in 1979 (TRS 641) for Myeloid leukaemia Added in 1979 (TRS 641) for Acute myeloid leukaemia with recurrent genetic abnormalities Added in 1979 (TRS 641) for Burkitt lymphoma including Burkitt leukaemia Added in 1979 (TRS 641) for Unspecified malignant neoplasms of unspecified sites Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of unspecified sites Added in 2023 (TRS 1049) for Anaplastic large cell lymphoma, ALK-positive Added in 2023 (TRS 1049) for Anaplastic large cell lymphoma, ALK-negative Added in 2023 (TRS 1049) for Langerhans cell histiocytosis
Wikipedia	Cytarabine
DrugBank	Cytarabine

Recommendations

Section Cytotoxic medicines

- Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial
- Parenteral > General injections > unspecified: 100 mg in vial powder for injection

Indications

Lymphoid leukaemia, not elsewhere classified

Myeloid leukaemia

Acute myeloid leukaemia with recurrent genetic abnormalities

Burkitt lymphoma including Burkitt leukaemia

Unspecified malignant neoplasms of unspecified sites

Anaplastic large cell lymphoma, ALK-positive

Anaplastic large cell lymphoma, ALK-negative

Langerhans cell histiocytosis